Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120,192,308
-
Total 13F shares
-
15,971,551
-
Share change
-
-1,481,493
-
Total reported value
-
$35,033,099
-
Price per share
-
$2.19
-
Number of holders
-
42
-
Value change
-
-$11,294,638
-
Number of buys
-
27
-
Number of sells
-
30
Institutional Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q1 2020
As of 31 Mar 2020,
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) was held by
42 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,971,551 shares.
The largest 10 holders included
Bratton Capital Management, L.P., VANGUARD GROUP INC, DG Capital Management, LLC, Bracebridge Capital, LLC, JPMORGAN CHASE & CO, Eversept Partners, LP, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, D. E. Shaw & Co., Inc., and BlackRock Inc..
This page lists
42
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.